NUCLIDIUM and Guerbet Form Strategic Partnership to Support theAdvancement of targeted Copper-based Radiotheranostics-- Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies,
production, and commercialization with Nuclidium’s in depth know-how of the copper radioisotope
production and theranostic development -Basel, Switzerland and Villepinte, France, May 22, 2024 – NUCLIDIUM and Guerbet (GBT) today
announced a strategic partnership to advance NUCLIDIUM’s diagnostic and therapeutic copper-based
radiopharmaceuticals. This partnership will provide NUCLIDIUM access to Guerbet’s knowledge andextensive network in diagnostic imaging, manufacturing, and clinical trials, aiding the progression ofNUCLIDIUM’s theranostic candidates towards commercialization. Guerbet has made a strategic, nonexclusive investment in NUCLIDIUM as part of the agreement. As part of the agreement, François Nicolas,Senior Vice President of R&D at Guerbet, will join NUCLIDIUM’s Board of Directors as an observer. No
further details of the agreement have been disclosed.
“Guerbet is a global leading expert in diagnostic imaging with a longstanding record in developing,manufacturing, and globally distributing medical imaging solutions. This collaboration emphasizes the valueof our innovative copper-based theranostic pipeline, which aims to provide cancer patients withcomprehensive solutions from the precise diagnosis to effective treatments. Our goal is to accelerate theclinical development of our unique product candidates and we look forward to gaining valuable strategic
insights from François and the Guerbet team,” said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM.
François Nicolas, Senior Vice President of R&D Guerbet added: “NUCLIDIUM leads in pioneering a newgeneration of targeted radiotheranostics that could vastly extend patient benefits. Targetedradiopharmaceuticals represent a significant advancement in cancer treatment, yet face supply limitations
and production challenges. NUCLIDIUM’s copper-based strategy presents a promising approach toaddress these issues, enhancing patient access and improving disease staging and treatment. This aligns
with Guerbet's growth strategy to broaden our core business areas. I am excited to support Leila and herteam in demonstrating the clinical value of its platform.”
NUCLIDIUM is advancing a unique pipeline of targeted copper-based radiopharmaceuticals leveraging
isotopes 61Cu and 67Cu. Its innovative platform facilitates a seamless transition from diagnostic to therapeutic
applications by merely exchanging the isotopes on the same tumor-targeting molecule. The company will
apply its easy-to-produce manufacturing process to enhance product availability and address major
challenges in radiotheranostic medicine to develop precise and effective theranostics for multiple solid tumor
types including prostate, colorectal, gastric, breast and pancreatic cancers as well as neuroendocrinetumors. The partnership with Guerbet is a critical pillar in NUCLIDIUM’s strategy to establish valuable
collaborations to advance its proprietary pipeline and ensure reliable supply chains for its copper-based
radiopharmaceuticals.
About NUCLIDIUMNUCLIDIUM is transforming precision oncology with its state-of-the-art copper-based
radiopharmaceuticals, delivering unmatched accuracy and accessibility for targeted cancer treatment anddiagnosis. Our innovative CuTrace™ platform merges copper radiometals with targeted cancer molecules,
speeding up the creation of new diagnostic and therapeutic solutions. This portfolio enhances safety andefficacy, offering cost-effective solutions for hospitals and patients. Our unique diagnostic-to-therapeuticmodel simplifies development, tackling manufacturing and distribution challenges to increase flexibility for
medical providers. Our diverse, interdisciplinary team is dedicated to revolutionizing precision radiooncology, significantly benefiting cancer patients.
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We
are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products,

medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast
media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10%of our sales to research and development in four centers in France, the United States and Israel. Guerbet(GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023.
For more information, please contact:
NUCLIDIUM
Leila Jaafar, CEO
Email: info@nuclidium.com
GuerbetChristine Allard, Head of Communications
Email: christine.allard@guerbet.com
Phone: +33 6 30 11 57 82
Investor/Media Contact NUCLIDIUM
Trophic Communications
Stephanie May, PhD
Email: may@trophic.eu
Phone: +49 171 1855682